Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Intima Bioscience, Inc.
Essen Biotech
H. Lee Moffitt Cancer Center and Research Institute
University of California, Irvine
Hadassah Medical Organization
Valo Therapeutics Oy
TCR2 Therapeutics
TCR2 Therapeutics
ImmunityBio, Inc.
ImmunityBio, Inc.
Immatics US, Inc.
Vall d'Hebron Institute of Oncology
Acepodia Biotech, Inc.
Essen Biotech
National Institutes of Health Clinical Center (CC)
BioEclipse Therapeutics
Gilead Sciences
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
Fred Hutchinson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Eastern Cooperative Oncology Group
BGI, China
Incyte Corporation
Genocea Biosciences, Inc.
Instituto Oncológico Dr Rosell
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Fred Hutchinson Cancer Center
GlaxoSmithKline
National Institutes of Health Clinical Center (CC)
Sichuan University
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Bioven Sdn. Bhd.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mayo Clinic
EMD Serono
UbiVac
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
Washington University School of Medicine
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
Bioven Sdn. Bhd.
University of Washington
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute